Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology

NCT06378190 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Refractory B-Cell Lymphoma
B-cell Lymphoma Recurrent

Interventions

BIOLOGICAL: CAR-T cells therapy

Sponsor

Instituto de Investigación Biomédica de Salamanca

Collaborators

[object Object]
[object Object]
[object Object]